Metis Global Partners LLC Lowers Stock Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Metis Global Partners LLC trimmed its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 12.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,356 shares of the company’s stock after selling 2,111 shares during the period. Metis Global Partners LLC’s holdings in GE HealthCare Technologies were worth $1,201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the stock. Mesirow Financial Investment Management Inc. lifted its position in shares of GE HealthCare Technologies by 39.6% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 4,084 shares of the company’s stock worth $383,000 after purchasing an additional 1,159 shares during the period. Cathy Pareto & Associates Inc. purchased a new stake in shares of GE HealthCare Technologies in the 4th quarter worth approximately $670,000. LMR Partners LLP purchased a new stake in shares of GE HealthCare Technologies in the 3rd quarter worth approximately $7,387,000. Principal Financial Group Inc. lifted its position in shares of GE HealthCare Technologies by 1.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,009,910 shares of the company’s stock worth $94,780,000 after purchasing an additional 19,010 shares during the period. Finally, B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of GE HealthCare Technologies in the 3rd quarter worth approximately $1,396,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on GEHC. Citigroup upped their price target on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Wells Fargo & Company upped their price target on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Finally, Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their target price for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, GE HealthCare Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $97.67.

GE HealthCare Technologies Trading Down 1.0 %

NASDAQ GEHC opened at $86.45 on Tuesday. The company has a fifty day simple moving average of $86.31 and a two-hundred day simple moving average of $86.14. The stock has a market cap of $39.53 billion, a P/E ratio of 19.97, a P/E/G ratio of 3.19 and a beta of 1.15. GE HealthCare Technologies Inc. has a 12-month low of $74.51 and a 12-month high of $94.80. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.88.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. The business had revenue of $5.32 billion during the quarter, compared to analysts’ expectations of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. On average, analysts forecast that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.